Abstract
Aim: To determine the efficacy of an interferon alpha and ribavirin combination treatment for Japanese patients infected with hepatitis C virus (HCV) of genotype 2, a multi-center study was retrospectively analyzed. Methods: In total, 173 patients with HCV genotype 2 started to receive interferon-alpha subcutaneously thrice a week and 600-800 mg of ribavirin daily for 24 wk. Results: The overall sustained virological response (SVR), defined as undetectable HCV RNA in serum, 24 wk after the end of treatment, was remarkably high by 84.4%, (146/173) by an intention-to-treat analysis. A significant difference in SVR was found between patients with and without the discontinuation of ribavirin (46.9% vs 92.9%), but no difference was found between those with and without a dose reduction of ribavirin. A significant difference in SVR was also found between patients with less than 16 wk and patients with 16 or more weeks of ribavirin treatment (34.8% vs 92.0%). Conclusion: The 24-wk interferon and ribavirin treatment is highly effective for Japanese patients with HCV genotype 2. The significant predictor of SVR is continuation of the ribavirin treatment for up to 16 weeks.
| Original language | English |
|---|---|
| Pages (from-to) | 784-790 |
| Number of pages | 7 |
| Journal | World Journal of Gastroenterology |
| Volume | 12 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - Feb 7 2006 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Gastroenterology
Cite this
Interferon alpha plus ribavirin combination treatment of Japanese chronic hepatitis C patients with HCV genotype 2 : A project of the Kyushu University Liver Diseases Study Group. / Furusyo, Norihiro; Katoh, Masaki; Tababe, Yuichi; Kajiwara, Eiji; Maruyama, Toshihiro; Shimono, Junya; Sakai, Hironori; Nakamuta, Makoto; Nomura, Hideyuki; Masumoto, Akihide; Shimoda, Shinji; Takahashi, Kazuhiro; Azuma, Koichi; Hayashi, Jun; Nakashima, H.; Murata, M.; Toyoda, K.; Takeoka, H.; Kuga, T.; Mitsutake, A.; Sugimoto, R.; Amagase, H.; Tominaga, S.; Yanagita, K.; Ogiwara, K.; Tokumatsu, M.; Tabata, S.; Yokota, M.; Tanaka, H.; Nagase, S.; Tsuruta, S.; Tada, S.; Nagano, M.; Honda, M.; Umeno, T.; Sugimura, T.; Ueno, S.; Miki, K.; Okubo, H.; Fujimoto, H.; Higuchi, N.; Shigematsu, S.; Higashi, N.
In: World Journal of Gastroenterology, Vol. 12, No. 5, 07.02.2006, p. 784-790.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Interferon alpha plus ribavirin combination treatment of Japanese chronic hepatitis C patients with HCV genotype 2
T2 - A project of the Kyushu University Liver Diseases Study Group
AU - Furusyo, Norihiro
AU - Katoh, Masaki
AU - Tababe, Yuichi
AU - Kajiwara, Eiji
AU - Maruyama, Toshihiro
AU - Shimono, Junya
AU - Sakai, Hironori
AU - Nakamuta, Makoto
AU - Nomura, Hideyuki
AU - Masumoto, Akihide
AU - Shimoda, Shinji
AU - Takahashi, Kazuhiro
AU - Azuma, Koichi
AU - Hayashi, Jun
AU - Nakashima, H.
AU - Murata, M.
AU - Toyoda, K.
AU - Takeoka, H.
AU - Kuga, T.
AU - Mitsutake, A.
AU - Sugimoto, R.
AU - Amagase, H.
AU - Tominaga, S.
AU - Yanagita, K.
AU - Ogiwara, K.
AU - Tokumatsu, M.
AU - Tabata, S.
AU - Yokota, M.
AU - Tanaka, H.
AU - Nagase, S.
AU - Tsuruta, S.
AU - Tada, S.
AU - Nagano, M.
AU - Honda, M.
AU - Umeno, T.
AU - Sugimura, T.
AU - Ueno, S.
AU - Miki, K.
AU - Okubo, H.
AU - Fujimoto, H.
AU - Higuchi, N.
AU - Shigematsu, S.
AU - Higashi, N.
PY - 2006/2/7
Y1 - 2006/2/7
N2 - Aim: To determine the efficacy of an interferon alpha and ribavirin combination treatment for Japanese patients infected with hepatitis C virus (HCV) of genotype 2, a multi-center study was retrospectively analyzed. Methods: In total, 173 patients with HCV genotype 2 started to receive interferon-alpha subcutaneously thrice a week and 600-800 mg of ribavirin daily for 24 wk. Results: The overall sustained virological response (SVR), defined as undetectable HCV RNA in serum, 24 wk after the end of treatment, was remarkably high by 84.4%, (146/173) by an intention-to-treat analysis. A significant difference in SVR was found between patients with and without the discontinuation of ribavirin (46.9% vs 92.9%), but no difference was found between those with and without a dose reduction of ribavirin. A significant difference in SVR was also found between patients with less than 16 wk and patients with 16 or more weeks of ribavirin treatment (34.8% vs 92.0%). Conclusion: The 24-wk interferon and ribavirin treatment is highly effective for Japanese patients with HCV genotype 2. The significant predictor of SVR is continuation of the ribavirin treatment for up to 16 weeks.
AB - Aim: To determine the efficacy of an interferon alpha and ribavirin combination treatment for Japanese patients infected with hepatitis C virus (HCV) of genotype 2, a multi-center study was retrospectively analyzed. Methods: In total, 173 patients with HCV genotype 2 started to receive interferon-alpha subcutaneously thrice a week and 600-800 mg of ribavirin daily for 24 wk. Results: The overall sustained virological response (SVR), defined as undetectable HCV RNA in serum, 24 wk after the end of treatment, was remarkably high by 84.4%, (146/173) by an intention-to-treat analysis. A significant difference in SVR was found between patients with and without the discontinuation of ribavirin (46.9% vs 92.9%), but no difference was found between those with and without a dose reduction of ribavirin. A significant difference in SVR was also found between patients with less than 16 wk and patients with 16 or more weeks of ribavirin treatment (34.8% vs 92.0%). Conclusion: The 24-wk interferon and ribavirin treatment is highly effective for Japanese patients with HCV genotype 2. The significant predictor of SVR is continuation of the ribavirin treatment for up to 16 weeks.
UR - http://www.scopus.com/inward/record.url?scp=33644889900&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33644889900&partnerID=8YFLogxK
U2 - 10.3748/wjg.v12.i5.784
DO - 10.3748/wjg.v12.i5.784
M3 - Article
C2 - 16521196
AN - SCOPUS:33644889900
VL - 12
SP - 784
EP - 790
JO - World Journal of Gastroenterology
JF - World Journal of Gastroenterology
SN - 1007-9327
IS - 5
ER -